Avantor Appoints New Executive VP and Transformation Leader

An update from Avantor ( (AVTR) ) is now available.

On April 17, 2026, Avantor, Inc. announced that Executive Vice President of Bioscience and Medtech Products, Benoit Gourdier, would transition into a new role supporting segment integration activities before leaving the company by December 31, 2026. On April 23, 2026, the company disclosed that Ludovic Brellier had been hired as Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer, effective May 1, 2026, signaling a leadership shift intended to drive integration and transformation in its bioscience and medtech operations.

The most recent analyst rating on (AVTR) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.

Spark’s Take on AVTR Stock

According to Spark, TipRanks’ AI Analyst, AVTR is a Neutral.

The score is held back primarily by weakening fundamentals and uncertainty in the most recent financial snapshot, plus conservative 2026 guidance (continued organic revenue declines, margin contraction, and wide free-cash-flow range). Consistently positive cash flow and prior leverage improvement provide the main support, while bearish technicals and a negative P/E further pressure the overall rating.

To see Spark’s full report on AVTR stock, click here.

More about Avantor

Avantor, Inc. operates in the life sciences and healthcare sector, providing bioscience and medtech products and related solutions. The company focuses on supporting research, biopharmaceutical production, and healthcare technologies through a broad portfolio aimed at laboratories, biopharma manufacturers, and medical technology customers.

Average Trading Volume: 11,042,533

Technical Sentiment Signal: Sell

Current Market Cap: $5.77B

Learn more about AVTR stock on TipRanks’ Stock Analysis page.